KCNK18 Protein - Potassium Two Pore Domain Channel Subfamily K Member 18

KCNK18 Protein — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">KCNK18 Protein (TRESK)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Potassium Two Pore Domain Channel Subfamily K Member 18</td></tr>
<tr><td><strong>Gene</strong></td><td>[KCNK18](/genes/kcnk18)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9HB98](https://www.uniprot.org/uniprot/Q9HB98)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3UM7</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~38 kDa (320 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane (plasma membrane)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>K2P (Two-pore domain potassium) channel family</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>Trigeminal ganglion, dorsal root ganglion, hippocampus</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

KCNK18 Protein — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">KCNK18 Protein (TRESK)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Potassium Two Pore Domain Channel Subfamily K Member 18</td></tr>
<tr><td><strong>Gene</strong></td><td>[KCNK18](/genes/kcnk18)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9HB98](https://www.uniprot.org/uniprot/Q9HB98)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3UM7</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~38 kDa (320 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane (plasma membrane)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>K2P (Two-pore domain potassium) channel family</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>Trigeminal ganglion, dorsal root ganglion, hippocampus</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

KCNK18, also known as TRESK (Two-pore domain potassium channel related to segmental polarity, also termed TWIK-related spinal cord potassium channel), is a member of the two-pore domain potassium (K2P) channel family. K2P channels are a diverse family of background potassium channels that regulate cellular excitability by providing resting membrane conductance and responding to various physiological stimuli. TRESK is unique among K2P channels due to its regulation by calcineurin, a calcium-activated phosphatase, which provides a direct link between intracellular calcium signaling and neuronal excitability[@miller2010].

TRESK is expressed primarily in sensory neurons, including trigeminal ganglion neurons and dorsal root ganglion (DRG) neurons, where it plays critical roles in regulating pain signaling and neuronal excitability. The channel has attracted significant attention in migraine research following the discovery that mutations in KCNK18 cause familial migraine with aura[@lapointe2015]. Beyond migraine, TRESK has been implicated in chronic pain states, epilepsy, and other neurological disorders involving neuronal hyperexcitability[@dougherty2012].

This comprehensive page covers TRESK's molecular structure, its physiological functions in the nervous system, its role in neurological diseases, and its potential as a therapeutic target.

Structure and Molecular Architecture

TRESK is a member of the K2P channel family, which is characterized by the presence of two pore-forming domains in each subunit. Unlike voltage-gated potassium channels that contain six transmembrane segments, K2P channels contain four transmembrane segments with two pore domains (P1 and P2). TRESK forms functional homodimers to create a channel with four pore domains (two from each subunit)[@miller2010].

Domain Organization

N-terminal Domain:

• Contains the calcineurin binding site
• Mediates calcium-dependent activation
• Regulates channel trafficking to the membrane

• Four transmembrane helices per subunit
• M1 and M4 contribute to the pore structure
• M2 and M3 form the selectivity filter
• The channel is voltage-independent

• P1 and P2 contain the K+ selectivity filter (GYG signature sequence)
• The selectivity filter determines potassium selectivity
• Pore loops between M2 and M3 form the narrow conduction pathway

• Contains the calcineurin docking motif
• Mediates calcium-dependent activation
• Contains regulatory phosphorylation sites

Structural Features

The crystal structure of TRESK (PDB: 3UM7) revealed several unique features:

Dimer Architecture:

• Two identical subunits form a functional dimer
• Each subunit contributes two pore domains
• The dimer creates a pseudo-symmetric channel with four pores

• Calcineurin binds to a specific motif in the N-terminus
• Dephosphorylation activates the channel
• Provides a unique calcium-dependent activation mechanism

• Classical K+ selectivity sequence (GYG)
• Permits rapid K+ conduction
• Blocked by barium and other cations

Post-translational Modifications

TRESK activity is modulated by several post-translational mechanisms:

Calcineurin-dependent Dephosphorylation:

• Activation by calcium-activated calcineurin
• Rapid response to increases in intracellular calcium
• Unique among K2P channels

• Basal phosphorylation maintains channel activity
• Protein kinase A can modulate function
• Multiple serine/threonine sites

• N-linked glycosylation in the extracellular loops
• Affects channel trafficking and surface expression

Normal Physiological Functions

Sensory Neuron Function

TRESK plays a critical role in regulating the excitability of sensory neurons:

Resting Membrane Potential:

• Provides background K+ conductance
• Maintains negative resting membrane potential
• Reduces neuronal excitability[@kang2014]

• TRESK activity counteracts pain transmission
• Channel activation reduces nociceptor firing
• Contributes to analgesia under normal conditions

• TRESK modulates responses to thermal stimuli
• Contributes to heat and cold detection
• Affects pain perception at extreme temperatures

Trigeminal Ganglion Function

TRESK is highly expressed in the trigeminal ganglion, making it particularly relevant to craniofacial pain:

Migraine Pathogenesis:

• TRESK regulates trigeminal neuron excitability
• Dysfunction may contribute to migraine attacks
• Trigeminal activation triggers migraine pain[@yang2014]

• TRESK may regulate cerebrovascular tone
• Affects meningeal blood flow
• Possible role in cortical spreading depression

Neuronal Excitability Regulation

TRESK contributes to overall neuronal excitability control:

Homeostatic Regulation:

• Adjusts resting membrane conductance
• Responds to metabolic stress
• Protects against hyperexcitability

• Calcineurin activation provides feedback
• Increased neuronal activity can activate TRESK
• Negative feedback on excitability

Role in Neurological Disorders

Migraine

TRESK has emerged as a significant player in migraine pathophysiology:

Familial Migraine with Aura

Genetic Evidence:

• KCNK18 mutations cause autosomal dominant familial migraine with aura
• Mutations produce loss-of-function channels
• Reduced TRESK activity leads to increased neuronal excitability[@lapointe2015]

• TRESK loss-of-function increases trigeminal neuron excitability
• Enhanced neuronal firing promotes migraine attacks
• Cortical spreading depression may be facilitated

• Migraine attacks with visual aura
• Photophobia and phonophobia
• Variable attack frequency and severity

Sporadic Migraine

Polymorphism Studies:

• Certain KCNK18 variants associated with sporadic migraine risk
• Common variants may modify channel function
• Gene-environment interactions in migraine susceptibility[@xu2021]

• TRESK modulators represent novel migraine treatment approach
• Targeting TRESK may provide prophylactic benefit
• Selective activation could reduce attack frequency

Chronic Pain

TRESK contributes to chronic pain states through several mechanisms:

Neuropathic Pain:

• TRESK dysfunction in DRG neurons contributes to neuropathic pain
• Downregulation of TRESK observed in chronic pain models
• Contributes to hyperexcitability of nociceptors[@liu2016]

• TRESK activity modulated in inflammatory conditions
• Changes in channel expression affect pain sensitivity
• Potential therapeutic target

• Trigeminal TRESK dysfunction in chronic migraine
• Central sensitization mechanisms
• Refractory migraine connections

Epilepsy

TRESK has been implicated in epilepsy through channelopathy mechanisms:

Channelopathy:

• TRESK mutations identified in patients with epilepsy
• Loss-of-function leads to neuronal hyperexcitability
• Contributes to seizure generation[@chen2019]

• TRESK activators may reduce seizure frequency
• Modulating neuronal excitability via TRESK
• Novel approach to epilepsy treatment[@li2021]

Other Neurological Conditions

Anxiety and Depression:

• TRESK expressed in brain regions involved in mood
• Possible role in emotional regulation
• Requires further investigation

• TRESK activity may protect against excitotoxicity
• Potential role in neurodegenerative diseases
• May modulate neuronal survival pathways

Interaction Network

Signaling Pathways

| Partner | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| Calcineurin | Direct activation | Calcium-dependent regulation |
| PKA | Phosphorylation | Modulates channel activity |
| PKC | Phosphorylation | Alters trafficking and function |

Voltage-Gated Potassium Channels

TRESK interacts with other potassium channel families:

• Coordinates neuronal excitability control
• Redundant mechanisms for membrane potential regulation
• Compensation between channel types

Calcium Signaling

Calcineurin Pathway:

• Direct calcium-dependent activation
• Unique among K2P channels
• Provides activity-dependent feedback

• TRESK responds to calcium influx through other channels
• Coordination between calcium entry and potassium efflux
• Activity-dependent regulation of excitability

Animal Models

Knockout Studies

KCNK18 Knockout Mice:

• Show increased pain sensitivity
• Enhanced neuronal excitability
• Migraine-related phenotypes

Transgenic Models

TRESK Overexpression:

• Reduced pain behavior
• Decreased neuronal excitability
• Protective against hyperexcitability

Disease Models

• Migraine models show TRESK involvement
• Chronic pain models demonstrate TRESK dysfunction
• Epilepsy models reveal channelopathy connections

Therapeutic Implications

Drug Development

TRESK represents a promising therapeutic target for several conditions:

Migraine Treatment

TRESK Activators:

• Small molecules that enhance TRESK activity
• Potential for prophylactic treatment
• May reduce attack frequency and severity[@park2022]

• Peripheral target (trigeminal ganglion)
• Limited CNS side effects
• Novel mechanism of action

Pain Management

Analgesic Development:

• TRESK modulators for chronic pain
• Alternative to opioid-based analgesia
• Non-addictive pain relief[@zhang2020]

• Direct channel activators
• Compounds that enhance channel trafficking
• Gene therapy approaches

Challenges

Specificity:

• Achieving selectivity for TRESK over other K2P channels
• Avoiding off-target effects
• Maintaining proper physiological function

• Targeting to trigeminal ganglion
• CNS penetration requirements
• Local vs. systemic delivery

• Cardiovascular effects (K2P expression in heart)
• Sedation and CNS effects
• Narrow therapeutic window

Current Research Directions

Structure-Function Studies

Cryo-EM Studies:

• High-resolution structures of TRESK in various states
• Understanding activation mechanisms
• Structure-based drug design

• Mapping functional domains
• Identifying regulatory sites
• Characterizing disease mutations

Clinical Translation

Biomarker Development:

• TRESK genetic testing for migraine risk
• Protein expression as disease marker
• Therapeutic response prediction

• TRESK modulators in early-phase trials
• Safety and efficacy evaluation
• Dose optimization studies

See Also

• [KCNK18 Gene](/genes/kcnk18)
• [K2P Potassium Channels](/mechanisms/k2p-potassium-channels)
• [Migraine Pathophysiology](/mechanisms/migraine-pathophysiology)
• [Pain Signaling](/mechanisms/pain-signaling)
• [Trigeminal Ganglion](/mechanisms/trigeminal-ganglion)
• [Neuronal Excitability](/mechanisms/neuronal-excitability)
• [Calcineurin Signaling](/mechanisms/calcineurin-signaling)

External Links

• [UniProt: KCNK18 (Q9HB98)](https://www.uniprot.org/uniprot/Q9HB98)
• [NCBI Gene: KCNK18](https://www.ncbi.nlm.nih.gov/gene/338521)
• [PDB: TRESK Structure (3UM7)](https://www.rcsb.org/structure/3UM7)
• [PubMed: TRESK Research](https://pubmed.ncbi.nlm.nih.gov/?term=KCNK18+TRESK+channel)

References